Hodgkin lymphoma—how much therapy do we need?

Lymphomas off the beaten track

“…Keeping high cure rates but also reducing toxicities to avoid secondary malignancies, cardiopulmonary long-term complications and to increase quality of life are the next goals. Barbara Lehner and Michael Panny [1] review the efforts of the German Hodgkin Study Group to de-escalate and discuss novel approaches including immunotherapy in the relapsed setting of Hodgkin lymphoma.…”